Fearing Second Offer Failure, Stada Management Appeals To Shareholders
Stada's management is scared an offer from two private-equity suitors will fail a second time due to shareholder inactivity or reluctance to accept the deal before its Aug 16 deadline.
You may also be interested in...
Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.
By stalking Stada, Cinven seems to be planning to use the German generics group as a base that can support later carve-outs of mature and undervalued products from larger pharma companies - but it faces a rival bidder in Advent, and more suitors could yet appear.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.